                         SEQUENCE LISTING

<110>  Healor Ltd.
 
<120>  METHOD FOR TREATMENT OF INFLAMMATORY DISEASE AND DISORDER

<130>  HLOR/007 PCT

<150>  61/405509
<151>  2010-10-21

<150>  61/293794
<151>  2010-01-11

<160>  39    

<170>  PatentIn version 3.5

<210>  1
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  1

Phe Ala Arg Lys Gly Ala 
1               5       


<210>  2
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  2

Phe Ala Arg Lys Gly Ala Leu Arg Gln 
1               5                   


<210>  3
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  3

Phe Ala Arg Lys Gly Ala Leu 
1               5           


<210>  4
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  4

Phe Ala Arg Lys Gly Ala Arg Gln 
1               5               


<210>  5
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  5

Thr Leu Asn Pro Gln Trp Glu Ser 
1               5               


<210>  6
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Modified with myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal alcohol group

<400>  6

Phe Ala Arg Lys Gly Ala Leu Arg Gln 
1               5                   


<210>  7
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal alcohol group

<400>  7

Phe Ala Arg Lys Gly Ala Leu Arg Gln 
1               5                   


<210>  8
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Modified with myristoylgroup

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  C-terminal alcohol group

<400>  8

Phe Ala Arg Lys Gly Ala Leu 
1               5           


<210>  9
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  C-terminal alcohol group

<400>  9

Thr Leu Asn Pro Gln Trp Glu Ser 
1               5               


<210>  10
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Modified with palmitoyl group

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal alcohol

<400>  10

Phe Ala Arg Lys Gly Ala Leu Arg Gln 
1               5                   


<210>  11
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Modified with palmitoyl group

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  C-terminal alcohol group

<400>  11

Phe Ala Arg Lys Gly Ala Arg Gln 
1               5               


<210>  12
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Modified with myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  C-terminal alcohol group

<400>  12

Phe Ala Arg Lys Gly Ala Leu 
1               5           


<210>  13
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal alcohol group

<400>  13

Phe Ala Arg Lys Gly Ala Leu Arg Gln 
1               5                   


<210>  14
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  14

Glu Ala Val Ser Leu Lys Pro Thr 
1               5               


<210>  15
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  15

Pro Tyr Ile Ala Leu Asn Val Asp 
1               5               


<210>  16
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  16

Pro Ala Trp His Asp 
1               5   


<210>  17
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  17

Leu Glu Pro Glu Ala Ala Ala Ala Ala Ala Gly Lys 
1               5                   10          


<210>  18
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  18

His Phe Glu Asp Trp Ile Asp 
1               5           


<210>  19
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  19

Val Tyr Val Ile Ile Asp Leu 
1               5           


<210>  20
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  C-terminal alcohol group

<400>  20

Glu Ala Val Ser Leu Lys Pro Thr 
1               5               


<210>  21
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  C-terminal alcohol group

<400>  21

Pro Tyr Ile Ala Leu Asn Val Asp 
1               5               


<210>  22
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  C-terminal alcohol group

<400>  22

Pro Ala Trp His Asp 
1               5   


<210>  23
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  C-terminal alcohol group

<400>  23

Leu Glu Pro Glu Ala Ala Ala Ala Ala Ala Gly Lys 
1               5                   10          


<210>  24
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  C-terminal alcohol group

<400>  24

His Phe Glu Asp Trp Ile Asp 
1               5           


<210>  25
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  C-terminal alcohol group

<400>  25

Val Tyr Val Ile Ile Asp Leu 
1               5           


<210>  26
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  26

Thr Arg Lys Arg Gln Arg Ala Met Arg Arg Arg Val His Gln Ile Asn 
1               5                   10                  15      


Gly 
    


<210>  27
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  27

Lys Arg Thr Leu Arg 
1               5   


<210>  28
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Modified with myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (17)..(17)
<223>  C-terminal alcohol group

<400>  28

Thr Arg Lys Arg Gln Arg Ala Met Arg Arg Arg Val His Gln Ile Asn 
1               5                   10                  15      


Gly 
    


<210>  29
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Modified with myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  C-terminal alcohol group

<400>  29

Lys Arg Thr Leu Arg 
1               5   


<210>  30
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  30

His Phe Glu Asp Trp Ile Asp 
1               5           


<210>  31
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  31

His Phe Glu Asp Trp Ile Asp His Phe Glu Asp Trp Ile Asp 
1               5                   10                  


<210>  32
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  32

Met Arg Ala Ala Glu Ala Ala Ala Ala Glu Pro Met 
1               5                   10          


<210>  33
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  33

Val Tyr Val Ile Ile Asp Leu His Phe Glu Asp Trp Ile Asp 
1               5                   10                  


<210>  34
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  C-terminal alcohol group

<400>  34

His Phe Glu Asp Trp Ile Asp His Phe Glu Asp Trp Ile Asp 
1               5                   10                  


<210>  35
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  C-terminal alcohol group

<400>  35

Met Arg Ala Ala Glu Ala Ala Ala Ala Glu Pro Met 
1               5                   10          


<210>  36
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  C-terminal alcohol group

<400>  36

His Phe Glu Asp Trp Ile Asp 
1               5           


<210>  37
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (14)..(14)
<223>  C-terminal alcohol group

<400>  37

Val Tyr Val Ile Ile Asp Leu His Phe Glu Asp Trp Ile Asp 
1               5                   10                  


<210>  38
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide

<400>  38

Ser Ile Tyr Arg Arg Gly Ala Arg Arg Trp Arg Lys Leu 
1               5                   10              


<210>  39
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Modified with myristoyl group

<220>
<221>  MISC_FEATURE
<222>  (13)..(13)
<223>  C-terminal alcohol group

<400>  39

Ser Ile Tyr Arg Arg Gly Ala Arg Arg Trp Arg Lys Leu 
1               5                   10              


